- Home
- LMB vs ATAI Comparison
LMB vs ATAI Comparison
Compare LMB & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LMB | ATAI |
|---|---|---|
| Founded | 1901 | 2018 |
| Country | United States | United States |
| Employees | 1400 | N/A |
| Industry | Engineering & Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 2014 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LMB | ATAI |
|---|---|---|
| Price | $81.48 | $3.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $116.67 | $15.13 |
| AVG Volume (30 Days) | 172.8K | ★ 4.1M |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 25.68 | N/A |
| EPS | ★ 3.23 | N/A |
| Revenue | ★ $646,804,000.00 | $308,000.00 |
| Revenue This Year | $15.96 | N/A |
| Revenue Next Year | $5.90 | N/A |
| P/E Ratio | $24.99 | ★ N/A |
| Revenue Growth | ★ 24.68 | N/A |
| 52 Week Low | $63.02 | $1.15 |
| 52 Week High | $154.04 | $6.73 |
Technical Indicators
Market Signals| Indicator | LMB | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 48.89 | 54.70 |
| Support Level | $77.96 | $3.60 |
| Resistance Level | $85.38 | $4.30 |
| Average True Range (ATR) | 4.34 | 0.20 |
| MACD | 0.54 | 0.03 |
| Stochastic Oscillator | 67.58 | 88.98 |
Price Performance
Historical ComparisonAbout LMB Limbach Holdings Inc.
Limbach Holdings Inc is a commercial specialty contractor in the fields of heating, ventilation, air conditioning, plumbing, electrical, and building controls for the design and construction of new and renovated buildings, maintenance services, energy retrofits, and equipment upgrades. It operates in two segments namely General Contractor Relationships (GCR) and Owner Direct Relationships (ODR). The company generates maximum revenue from the ODR segment.
About ATAI ATAI Life Sciences N.V.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.